IFNα has been used to treat malignant and viral disorders for more than 25 years. Its efficacy
is likely the consequence of its broad range of biologic activities, including direct effects on …

Idiopathic myelofibrosis is a chronic myeloproliferative disorder characterized by bone
marrow fibrosis, extramedullary haematopoiesis and a leucoerythroblastic blood picture …

Abstract In a 20-year period, 223 patients (median age, 64.8 years) with myelofibrosis with
myeloid metaplasia (MMM) had therapeutic splenectomy at our institution. Primary …

Within recent years data has accumulated demonstrating the efficacy of recombinant
interferon alpha2 (rIFN-alpha2) in the treatment of chronic myeloproliferative neoplasms …

The Philadelphia negative myeloproliferative neoplasms, including polycythemia vera,
essential thrombocythemia, and myelofibrosis, are associated with substantial vascular and …

Background/Aim The interactions between the gut and liver have been described in the
progression of non-alcoholic steatohepatitis (NASH). The aim of this study was to develop …

In recent years, several studies have shown that IFN-α2 is able to induce molecular
remissions with undetectable JAK2V617F in a subset of patients with essential …

Polycythemia vera, essential thrombocytosis, and myelofibrosis are chronic Philadelphia-
negative myeloproliferative neoplasms that are characterized by clonal hematopoiesis …

The conventional treatment of myelofibrosis involves a wait‐and‐see approach for
asymptomatic patients, oral chemotherapy for the hyperproliferative forms of the disease …

Background Myelofibrosis (MF) is a Philadelphia chromosome–negative myeloproliferative
neoplasm characterized by progressive bone marrow failure, increased risk of progression …